Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Aug 14;18(1):380.
doi: 10.1186/s13063-017-2126-x.

A randomized, multi-center, prospective study comparing best medical treatment versus best medical treatment plus renal artery stenting in patients with hemodynamically relevant atherosclerotic renal artery stenosis (RADAR) - one-year results of a pre-maturely terminated study

Thomas Zeller  1 , Hans Krankenberg  2 , Andrejs Erglis  3 , Erwin Blessing  4 , Torsten Fuss  5   6 , Dierk Scheinert  7 , Ralf Weser  8 , Beatrix B Doerr  9 , Wilfrid D Yollo  10 , Joerg Radermacher  11 ; RADAR Investigators
Affiliations
Randomized Controlled Trial

A randomized, multi-center, prospective study comparing best medical treatment versus best medical treatment plus renal artery stenting in patients with hemodynamically relevant atherosclerotic renal artery stenosis (RADAR) - one-year results of a pre-maturely terminated study

Thomas Zeller et al. Trials. .

Abstract

Background: The indications for conservative "best medical treatment" (BMT) versus additional renal artery stenting are a matter of ongoing debate. The RADAR study aimed to evaluate the impact of percutaneous renal artery stenting on the impaired renal function in patients with hemodynamically significant atherosclerotic renal artery stenosis (RAS).

Methods: RADAR is an international, prospective, randomized (1:1) controlled study comparing BMT alone versus BMT plus renal artery stenting in patients with duplex sonographic hemodynamically relevant RAS. Follow-up assessments were at 2, 6, and 12 months and at 3 years. The primary endpoint was change in estimated glomerular filtration rate (eGFR) at 12 months.

Results: Due to slow enrollment, RADAR was terminated early after inclusion of 86 of the scheduled 300 patients (28.7%). Change in eGFR between baseline and 12 months was 4.3 ± 15.4 ml/min/1.73 m2 (stent group) and 3.0 ± 14.9 ml/min/1.73 m2 (BMT group), p > 0.999. Clinical event rates were low with a 12-month composite of cardiac death, stroke, myocardial infarction, and hospitalization for congestive heart failure of 2.9% in the stent and 5.3% in the BMT group, p = 0.526, and a 3-year composite of 14.8% and 12.0%, p = 0.982. At 3 years, target vessel (re-)vascularization occurred in one patient (3.0%) in the stent group and in 8 patients (29.4%) in the BMT group.

Conclusion: In RADAR, outcomes of renal artery stenting were similar to BMT. These results have to be interpreted with the caveat that the study did not reach its statistically based sample size.

Trial registration: Clinicaltrials.gov, NCT00640406. Registered on 17 March 2008.

Keywords: Best medical therapy; Best medical treatment; Hypertension; Renal artery stenosis; Renal artery stenting; Renal function.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study was approved by the respective ethics committees. A respective list is available as a separate file. All patients gave written informed consent.

Consent for publication

Not applicable.

Competing interests

TZ has received consulting fees from Medtronic, Gore, Cook, Bard, Covidien, Biotronik, and Abbott Vascular, and serves on the advisory board of Medtronic, Boston Scientific, and Gore. AE acts as a consultant for and is on the speakers’ bureaus of Abbott Vascular, Biosensors, Biotronik, Boston Scientific, Cordis (Johnson and Johnson), and Medtronic, and has received research contracts from Abbott Vascular and Boston Scientific. DS acts as a member/consultant of the advisory board of Abbott, Biotronik, Boston Scientific, Cook Medical, Cordis, CR Bard, Gardia Medical, and Medtronic/Covidien. BBD and WDY receive consultant fees from Biotronik. YHK, JR, EB, and RW have nothing to disclose.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Patient flow chart. There were 3 patients in the best medical treatment (BMT) group who received bailout stenting before 6 months, 3 patients received it between 6 and 12 months, and 4 patients received it beyond 12 months. ITT intention to treat, FUP follow up
Fig. 2
Fig. 2
Percentage of patients with change in antihypertensive medication compared to baseline. There was no statistical significant difference between the groups. BMT best medical treatment
See this image and copyright information in PMC

References

    1. Rimmer JM, Gennari FJ. Atherosclerotic renovascular disease and progressive renal failure. Ann Intern Med. 1993;118:712–9. doi: 10.7326/0003-4819-118-9-199305010-00010. - DOI - PubMed
    1. Tollefson DF, Ernst CB. Natural history of atherosclerotic renal artery stenosis associated with aortic disease. J Vasc Surg. 1991;14:327–31. doi: 10.1016/0741-5214(91)90084-8. - DOI - PubMed
    1. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med. 2001;344:431–42. doi: 10.1056/NEJM200102083440607. - DOI - PubMed
    1. Mohan IV, Bourke V. The management of renal artery stenosis: an alternative interpretation of ASTRAL and CORAL. Eur J Vasc Endovasc Surg. 2015;49:465–73. doi: 10.1016/j.ejvs.2014.12.026. - DOI - PubMed
    1. Jennings CG, Houston JG, Severn A, Bell S, Mackenzie IS, Macdonald TM. Renal artery stenosis-when to screen, what to stent? Curr Atheroscler Rep. 2014;16:416. doi: 10.1007/s11883-014-0416-2. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data